clinical trial | Q30612 |
P3098 | ClinicalTrials.gov ID | NCT02308748 |
P6099 | clinical trial phase | phase I clinical trial | Q5452194 |
P582 | end time | 2014-06-01 | |
P4135 | maximum age | 35 | |
P1050 | medical condition | long QT syndrome | Q653924 |
P2899 | minimum age | 18 | |
P1132 | number of participants | 22 | |
P4844 | research intervention | dofetilide | Q3712521 |
(RS)-mexiletine hydrochloride | Q27107357 | ||
calcium oxalate | Q412399 | ||
P580 | start time | 2014-05-01 | |
P8363 | study type | interventional study | Q78089383 |
P1476 | title | Five Period Crossover Study of the Ability of Late Sodium or Calcium Current Block (Mexiletine, Lidocaine, or Diltiazem) to Balance the Electrocardiographic Effects of hERG Potassium Current Block (Dofetilide or Moxifloxacin) |
Search more.